Gold prices edge higher on raised Fed rate cut hopes
Revolution Medicines, Inc. (NASDAQ:RVMD), a biopharmaceutical company with a market capitalization of $7.4 billion, announced today that Barbara Weber, M.D., has resigned from the company’s board of directors, effective immediately prior to the upcoming annual meeting of stockholders scheduled for June 26, 2025.
Dr. Weber’s departure includes her positions as a board member and her roles on both the Nominating and Corporate Governance Committee and the Research & Development Committee.
According to the company’s SEC filing, Weber’s resignation is connected to the activation of a clinical study under the ongoing collaboration between Revolution Medicines and Tango Therapeutics, Inc. The filing specifically noted that her decision "was not a result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices."
Revolution Medicines is a biopharmaceutical company focused on developing novel targeted therapies. The company’s common stock trades on the Nasdaq Stock Market under the symbol "RVMD," while its warrants to purchase 0.1112 shares of common stock expiring in 2026 trade under "RVMDW."
The company’s 2025 annual meeting of stockholders is scheduled to take place at 7:30 a.m. PT on June 26, 2025.
In other recent news, Revolution Medicines has made several notable announcements that are capturing investors’ attention. The company reported a strong cash position of $2.1 billion at the end of Q1 2025, despite a net loss of $213.4 million, which is up from $116 million the previous year. This financial update comes as Revolution Medicines continues to advance its cancer treatment pipeline, focusing on RAS inhibitors, with increased R&D expenses reflecting its commitment to these clinical trials. Additionally, Revolution Medicines has initiated a Phase 3 trial for its lung cancer drug, daraxonrasib, aimed at treating non-small cell lung cancer with specific RAS mutations.
On the analyst front, Oppenheimer has maintained an Outperform rating for Revolution Medicines, citing strong clinical programs and potential pipeline updates. Meanwhile, H.C. Wainwright adjusted its price target for the company to $72.00, while maintaining a Buy rating, highlighting promising clinical results for elironrasib monotherapy in lung cancer treatment. These developments underscore the company’s strategic initiatives to position its RAS inhibitors as leading therapies in oncology. Revolution Medicines is also expanding its commercial capabilities in the U.S., preparing for potential product launches, and exploring international opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.